Hafslund Nycomed/Diatech deal gives Nycomed first access to peptide-based nuclear imaging agents.
Executive Summary
HAFSLUND NYCOMED/DIATECH COLLABORATION ON IMAGING AGENTS is the Norwegian firm Hafslund Nycomed's first venture into nuclear medicines, the companies said Aug. 14. Nycomed is the largest medical imaging contrast media company in the world, and through a $10 mil. equity investment in Londonderry, N.H.-based Diatech, it will have access to Diatech's proprietary TechTide peptide-based nuclear medicine imaging agents.